| scholarly article | Q13442814 |
| P50 | author | Valentina Masola | Q30513702 |
| Gianluigi Zaza | Q37635234 | ||
| Loreto Gesualdo | Q53073703 | ||
| Fabio Sallustio | Q57015434 | ||
| Simona Granata | Q57663671 | ||
| Paola Pontrelli | Q58898361 | ||
| Antonio Lupo | Q67598891 | ||
| Giuseppe Grandaliano | Q96016958 | ||
| P2093 | author name string | Giovanni Gambaro | |
| P2860 | cites work | Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion | Q21093315 |
| The Gene Ontology project in 2008 | Q24649653 | ||
| Statistical significance for genomewide studies | Q24681264 | ||
| Biological interplay between proteoglycans and their innate immune receptors in inflammation | Q27005610 | ||
| Molecular classification of cancer: class discovery and class prediction by gene expression monitoring | Q27861072 | ||
| Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance | Q28264895 | ||
| Inflammation, atherosclerosis, and coronary artery disease | Q29547232 | ||
| Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease | Q33495688 | ||
| Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas | Q33801290 | ||
| Heparanase, a potential regulator of cell-matrix interactions | Q33984496 | ||
| Uremic toxicity: urea and beyond | Q34328318 | ||
| Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis | Q34398151 | ||
| Haemodialysis, atherosclerosis and inflammation-identifying molecular mechanisms of chronic vascular disease in ESDR patients | Q34576135 | ||
| Uremia | Q34693851 | ||
| A specific immune transcriptomic profile discriminates chronic kidney disease patients in predialysis from hemodialyzed patients | Q34714685 | ||
| Immunological basis of inflammation in dialysis | Q34766523 | ||
| Versican: a versatile extracellular matrix proteoglycan in cell biology | Q34858300 | ||
| Urine glycoprotein profile reveals novel markers for chronic kidney disease | Q35380506 | ||
| Role of Monocytes in Atherogenesis | Q35541858 | ||
| Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells | Q35668839 | ||
| LPS induced inflammatory responses in human peripheral blood mononuclear cells is mediated through NOX4 and Giα dependent PI-3kinase signalling. | Q35800372 | ||
| The biology of vascular endothelial growth factors. | Q36017169 | ||
| Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. | Q36109189 | ||
| The interaction of versican with its binding partners | Q36208033 | ||
| Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation | Q36361058 | ||
| An introduction to proteoglycans and their localization | Q36481630 | ||
| Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis | Q36562440 | ||
| Plasma concentrations of extracellular matrix protein fibulin-1 are related to cardiovascular risk markers in chronic kidney disease and diabetes. | Q36604574 | ||
| Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients | Q36666840 | ||
| Fluid balance, dry weight, and blood pressure in dialysis | Q36719790 | ||
| Metabolic syndrome and kidney disease | Q37053432 | ||
| Proteoglycans: from structural compounds to signaling molecules | Q37513784 | ||
| Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients. | Q37646842 | ||
| The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis | Q37649205 | ||
| Strategies for improving long-term survival in peritoneal dialysis patients | Q37739699 | ||
| Developmental and pathological angiogenesis | Q37901035 | ||
| From -omics to personalized medicine in nephrology: integration is the key. | Q38066427 | ||
| A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. | Q39254044 | ||
| Reactive oxygen species mediate high glucose-induced heparanase-1 production and heparan sulphate proteoglycan degradation in human and rat endothelial cells: a potential role in the pathogenesis of atherosclerosis | Q39572643 | ||
| Dialysis-related systemic microinflammation is associated with specific genomic patterns. | Q40148485 | ||
| C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients | Q41721897 | ||
| The burden of chronic kidney disease | Q43237849 | ||
| Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey | Q44261213 | ||
| Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study | Q46101874 | ||
| Short-term effects of bicarbonate/lactate-buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study | Q46208487 | ||
| Cytokines and bioincompatibility | Q47776372 | ||
| Biocompatibility of haemodialysis membranes determined by gene expression of human leucocytes: a crossover study. | Q53437622 | ||
| VEGF-enhanced proliferation under hypoxia by an autocrine mechanism in human vascular smooth muscle cells. | Q54546894 | ||
| ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. | Q55041285 | ||
| P433 | issue | 1 | |
| P921 | main subject | renal dialysis | Q202301 |
| transcriptome | Q252857 | ||
| P304 | page(s) | 52-64 | |
| P577 | publication date | 2013-11-04 | |
| P1433 | published in | Experimental Biology and Medicine | Q15716535 |
| P1476 | title | Dialysis-related transcriptomic profiling: the pivotal role of heparanase | |
| P478 | volume | 239 |
| Q90366970 | End-stage renal disease is different from chronic kidney disease in upregulating ROS-modulated proinflammatory secretome in PBMCs - A novel multiple-hit model for disease progression |
| Q43812376 | Heparanase and macrophage interplay in the onset of liver fibrosis |
| Q28083753 | Impact of heparanase on renal fibrosis |
| Q59799492 | Inhibition of heparanase protects against chronic kidney dysfunction following ischemia/reperfusion injury |
| Q26740125 | Transcriptomics: A Step behind the Comprehension of the Polygenic Influence on Oxidative Stress, Immune Deregulation, and Mitochondrial Dysfunction in Chronic Kidney Disease |
Search more.